As a leading enterprise in China’s genetic testing industry, BGI combines strong R & D self-developed instruments and reagents to effectively control costs. The rapid growth of the reproductive and health businesses has formed a scale effect and BGI is active in such promising fields as complex diseases and drug research and development. Operating income for Jan. to Sept. 2017 was 1.447 billion yuan, an increase of 15 %, and net profits rose by 21 % to 312 million yuan. China’s genetic sequencing market size was 5.4 billion yuan in 2016 and is expected to exceed 10 billion yuan in 2020. The global genetic testing market was estimated at 20 billion US dollars in 2016.

China Bio news release, November 15, 2017